Studies have shown that pharmaceutical care interventions have the potential of reducing hospital stay and drug therapy problems; it can also improve patients' quality of life. The primary objectives of this study was to show how pharmaceutical care interventions could resolve actual drug therapy problems and prevent potential drug therapy problems; also, to assess the change in the quality of life of hypertensive patients after such interventions. An uncontrolled prospective study was done. Hypertensive patients were recruited at the Medical Out-patients department (MOD) of Central Hospital Warri. Initially 104 patients were recruited, however, a total of 65 eligible patients were eventually used to asses for quality of life. Data were obtained using data collection forms; blood pressure was monitored using a sphygmomanometer, and patients were scheduled for follow up periodically for 6 months.
Introduction
Globally, there have been significant changes in health care systems in respect of their quality and processes, and this had been specifically demonstrated in the practice of pharmacy. A dramatic shift in the way pharmacy had been practiced was demonstrated in the newly emerging Pharmaceutical care practice, defined as "the responsible provision of drug therapy to achieve definite outcomes that improve a patient"s quality of life" The definition proposed by Hepler and Strand highlighted three major outcomes of pharmaceutical care 1 . These outcomes are humanistic, economic and clinical.
The specific responsibilities of a pharmaceutical care practitioner include ensuring that the most effective and safest drugs are prescribed to patients and that a patient"s drug therapy is convenient enough to be followed as indicated.
It is the pharmacist"s responsibility to ensure that the patient is able to adhere to medication instruction in order to produce positive outcomes. In addition, the pharmacist is responsible for identifying, resolving and preventing Drug Therapy problems (DTPs). Identifying DTPs is one of the objectives of the pharmaceutical care process.
Pharmacists are expected to acquire the necessary skills to identify potential and actual drug therapy problems better than anyone else. Relevant patient data must be acquired, and critical thinking skills applied. All medications must be compared to make sure that they serve a therapeutic purpose.
Clinical pharmacists play an important role in identifying and resolving DTPs through cooperation with patients and other health care providers. Potential and actual DTPs can be identified thorough medication profile reviews, and these problems can be prevented by monitoring therapeutic plans 2 . A number of actual DTPs can be resolved with patient counselling and recommendations to prescribers. with one or two questions per domain, hence its usefulness in a study of this type.
The Quality Metric"s SF-12v2® scoring software was the key used in measuring QoL in this study.
Methods

Study design
This was a non-randomised, single-site, uncontrolled, prospective study. A descriptive study design was used to identify and DTPs.
The experimental intervention was a pharmaceutical care (PC)
protocol, in which the researcher (the pharmacist)in union with the doctors assigned to the patients, the patients and their caregivers, design, implement and monitor a Pharmaceutical care
Plan (PCP).
A cross-sectional study design, using the Quality of life short form (SF-12) health surveyed questionnaire, was used to assess patients" quality of life.
Study setting
This study was carried out in the Medical Outpatient Department of Central Hospital Warri, Delta State, Nigeria. This site was chosen because it is located in the heart of the city, it also has the highest traffic of patients; previous studies on nonadherence by hypertensive patients have been done and confirmed as one reason for poor treatment outcomes. The hospital is a Secondary health care facility which offers comprehensive health care services to the people in the State and its environs. The hospital is comprised of both in-and outpatients. There are various wards and departments situated within the hospital.
Population/sampling method
During 6 weeks period, all hypertensive patients who came to the Medical Out-patients Department (MOD) of the hospital were identified as potential candidates for the study. Patients were eligible to participate if they met the following criteria.
Inclusion and exclusion criteria
Inclusion Exclusion criteria: Those who did not meet the criteria above, hypertensive patients on admission, those who had psychiatric illness, were chronically ill-looking, were with memory impairment, manifested hypertensive emergency or nonconsenting was excluded from the study.
Patients
Patients were consecutively recruited within a 4 -6 week period (this was because the usual re-call period in that department
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Patients were addressed on the purpose and the nature of the study and were asked to give their oral consent as to indicate their interest in being part of the study. On that basis, patients were recruited within 4 -6 weeks, during which a 1 week pilot study was done, and relevant amendments subsequently made.
Out of 104 recruited, 1 patient died and 38 were eventually excluded because they were not followed up until the end of the study. Eventually, 65 outpatients were followed up between January 2013 and July 2013 at The Central Hospital, Warri, Delta State.
Research instrument
Data collection instrument included: A blood pressure monitor (digital sphygmomanometer) to measure blood pressure of patients at each visit, pharmaceutical care intervention forms to document patient information, and a standardized form to obtain patient subjective data for assessing patients" quality of lifeQuality Metric® SF-12V2 survey forms. Appointment cards were also designed specifically for this research purpose to facilitate patient follow up.
Data collection procedure
Data collection procedures included blood pressure monitoring and patient interviews to collect data on drug therapy profile and intervention, and data collection to assess patients" QoL at baseline and end of study.
Data collection was done by the pharmacist and her research assistant via oral interview, using a comprehensive pharmaceutical care documentation format, which was based on the pharmaceutical care (PC) steps. This format was appropriate for this study because it prompted the pharmacist to acquire the relevant subjective and objective data as well as to complete other steps involved in the pharmaceutical care process 9 .
Documentation of the following patient data was done at the first visit: patient"s chief complaint and/or doctor"s diagnosis, family history, social history, past medical history, past medication history, present medication history (based on doctor"s prescription). Systolic and diastolic blood pressure readings were determined at every visit, using a digital sphygmomanometer; three measures were taken at five minutes interval and averaged.
Medication assessment was done to identify the ratio of antihypertensive drugs prescribed to the total number of medications indicated in the patient"s prescription. QoL at baseline was assessed using the Quality metric® SF12 survey.
Also, Potential and actual DTPs were identified by interview and physical assessment of the patients.
For the period of 6 months within which the study was The data for scoring QoL using the SF12 health survey forms were generated by the research pharmacist at the beginning of the study (baseline) and at the end of intervention.
Other interventions included monitoring of blood pressure at each visit. Patients were also educated on the need for selfmonitoring procedures, such as possessing their own sphygmomanometer and monitoring their blood pressure regularly. They were trained on how to measure their blood pressure using digital blood pressure monitors. Patients were also followed up with telephone calls. For patients who needed urgent attention, appointments were made with their physician to see them promptly for review. The SF-12Health survey form was administered to patients at baseline (first interview) and at the end of the study.
Assessment of quality of life (QoL)
Scoring for the SF12 health survey was based on an algorithm.
For this study, the Quality Metric Health OutcomesTM scoring software, version 4.5 was used, of which license was obtained specifically for this study. 
Inferential statistics
Correlation was done to test for association between the number of DTPs resolved/prevented and the QoL at baseline.
Correlation was also done for the number of DTPs resolve/prevented and QoL at the end of study. The paired Student"s t-test was used to compare QoL of the patients at baseline and their QoL at the end of study. A significance level of P< 0.05 was used for all statistical tests.
Results
Number of outpatients who were eventually followed up between January 2013 and July 2013 was 65.
Out of the 65 patients, who were eventually followed up until Blood pressure readings were documented at each visit. Mean systolic and diastolic blood pressure were calculated, at baseline and at end of study. Systolic blood pressure at the end of study was higher while the post-treatment diastolic blood pressure was slightly lower (87.7 ± 18.2 mmHg) than that at base line (89.3 ± 18.5 mmHg). Changes in blood pressure formed the basis for further investigations and follow up. Table   2a shows mean blood pressure pre-and post-study. Blood pressure was well controlled in 30 patients; post treatment systolic and diastolic blood pressure was lower at the end of the study. There was statistically significant improvement in blood pressure after intervention. Table 2b shows mean blood pressure for the 30 patients that had blood pressure controlled after intervention. 
Drug therapy problems resolved and prevented
Number of drug therapy problems identified in 65 patients were 104; an average of 1.6 DTP per patient. Quantity of potential DTPs prevented were 20, and 20 could not be prevented as at the end of the study. Actual number of DTPs resolved were 52, and 12 could not be resolved as at the end of the study (Tables   3) . 
Quality of life (QoL): Assessment and analysis
The Quality Metric®12Short form (SF-12) survey was used. At baseline and at end of study, the following 8 domains were scored as follows (Table 6 ).
These scores range from 0 -100, where 0 indicates poor health and anything above the "norm" (50) indicates good health.
Comparing QOL at baseline and at end of study:
Using student t-test to compare QOL at baseline, to that done at the end of the study, QoL scores before and after the intervention assessed by the use of SF12, were used. At 95% inverse relationship between Bodily pain (BP) and QoL ( -.271 at p<0.05) ( Table 8) . 
Discussions
The study lasted for six months, similar to the duration of another study done in Portugal 13 , indicating that 6 months intervention was enough to develop noticeable outcomes in pharmaceutical care. About half of the population sample, had their blood pressure well controlled by the end of the study;
however, this was a slightly lower proportion of patients compared to other studies where PC was done for hypertensive patients 13, 14 . This can be attributable to the high prevalence of inappropriate adherence and other factors observed in this study. Several studies have shown that involvement of pharmacists in the management of hypertensive patients improved treatment outcomes 13, 15 . (This study provided evidence for the benefits of a patient-focused role of the pharmacist in identifying and resolving drug-related problems in the patient population studied.
The co-operation between the pharmacist and the clinician also was a key to resolving and/or preventing DTPs in this study.
However, percentage DTP resolved and prevented were relatively lower in this study than observed in other studies (50%) as compared to (83%) detected actual DTPs 13 .
Generic instruments, such as the SF-36, SF-12, SF-8, can accurately assess all significant health aspects and reflect the impact of a disease on an individual 16, 8 . These types of instruments have been used to study groups of patients with different diseases, ambulatory populations, and populations with chronic health conditions.
Evidence from this study showed that there was an improvement in some of the domains of the QoL of the patients assessed at the end of the study; these were: all the domains in the Mental Component Summary (MCS), and bodily pain. This evidence is relevant since one of the goals of therapy is to improve quality of life, and this is in line with other studies done which reported improvements in the QoL of the subjects;
examples are in patients with asthma 17 , diabetes 18 , migraine 19 and cardiovascular diseases 20 .
QoL at baseline, PCS showed 56% of the group were below the population norm, while 12% where rated above the norm. The MCS 39% were below the norm and 38% above the norm.
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At the end of the study, there was a strong association between MCS and BP (bodily pain). In other words, bodily pain and the mental component summary of the individuals affected their quality of life as at the end of the study. Note that for bodily pain, there is an inverse relationship (QoL improved as bodily pain decreased). There was also remarkable improvement at the Vitality and Mental health domains; 49% of the population had an MCS above the norm; PCS also increased to 28%.
In comparison, there was a general improvement in the MCS, as compared to the PCS, at the end of the study.
Implication of findings
The role of the hospital pharmacist should therefore, extensively involve pharmaceutical care in order to resolve or prevent these DTPs. Documentation and subsequent follow up of these patients would include follow-up visits. Pharmaceutical care intervention would eventually lead to successful treatment outcomes, and overall improvement in patient"s quality of life.
Conclusions
The overall benefit of pharmaceutical care intervention was an improvement in the quality of life of the patients basically in the following domains of QoL: Vitality, Social Function, Role
Emotional, and Mental Health.
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